目的 探討藤黃健骨膠囊聯(lián)合唑來膦酸注射液治療老年原發(fā)性骨質疏松的臨床療效。方法 選取2016年5月-2017年4月瀘州市人民醫(yī)院收治的老年原發(fā)性骨質疏松患者120例為研究對象，按照隨機數(shù)字表法將所有患者分為對照組和治療組，每組各60例。對照組靜脈滴注唑來膦酸注射液，5 mg加入到生理鹽水500 mL中，滴速30滴/min，靜滴時間不低于30 min，1次/年。治療組在對照組治療基礎上口服藤黃健骨膠囊，1 g/次，2次/d。兩組患者連續(xù)治療12個月。觀察兩組的臨床療效，比較兩組的血清因子水平、骨密度（BMD）、視覺模擬評分法（VAS）評分。結果 治療后，對照組和治療組的總有效率分別為78.33%、91.67%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組基質金屬蛋白酶13（MMP-13）、MMP-13/TIMP-1顯著降低，金屬蛋白酶抑制因子（TIMP-1）明顯升高，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組血清因子水平明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組腰椎、股骨頸、Wards三角區(qū)的BMD明顯升高，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組BMD明顯高于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組VAS評分明顯降低，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組VAS評分明顯低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 藤黃健骨膠囊聯(lián)合唑來膦酸注射液治療老年原發(fā)性骨質疏松具有較好的臨床療效，可調節(jié)骨代謝指標，提高骨密度，減少疼痛，具有一定的臨床推廣應用價值。

Objective To investigate the clinical effect of Tenghuang Jiangu Capsules combined with Zoledronic Acid Injection in treatment of senile primary osteoporosis. Methods Patients (120 cases) with senile primary osteoporosis in Luzhou People's Hospital from May 2016 to April 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were iv administered with Zoledronic Acid Injection, 5 mg added into normal saline 500 mL, the drop speed was 30 drops/min, and the drop time was not less than 30 min, once yearly. Patients in the treatment group were po administered with Tenghuang Jiangu Capsules on the basis of the control group, 1 g/time, twice daily. Patients in two groups were treated for 12 months. After treatment, the clinical efficacies were evaluated, and serum levels of factors, BMD, and VAS scores in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 78.33% and 91.67%, respectively, and there was difference between two groups (P<0.05). After treatment, MMP-13 and MMP-13/TIMP-1 levels in two groups were significantly decreased, but the TIMP-1 levels in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the serum levels of factors in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the BMD of lumbar vertebrae, femoral neck and Wards triangle in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the BMD in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, VAS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the VAS scores in the treatment group were significantly lower than that in the control group, with significant difference between two groups (P<0.05). Conclusion Tenghuang Jiangu Capsules combined with Zoledronic Acid Injection has clinical curative effect in treatment of senile primary osteoporosis, can regulate bone metabolism index, increase BMD, and reduce patient's pain, which has a certain clinical application value.